Annual CFI
$50.45 M
+$30.72 M+155.67%
December 31, 2023
Summary
- As of February 26, 2025, RLMD annual cash flow from investing activities is $50.45 million, with the most recent change of +$30.72 million (+155.67%) on December 31, 2023.
- During the last 3 years, RLMD annual CFI has risen by +$84.90 million (+246.46%).
- RLMD annual CFI is now at all-time high.
Performance
RLMD Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$16.14 M
+$2.13 M+15.19%
September 30, 2024
Summary
- As of February 26, 2025, RLMD quarterly cash flow from investing activities is $16.14 million, with the most recent change of +$2.13 million (+15.19%) on September 30, 2024.
- Over the past year, RLMD quarterly CFI has increased by +$6.08 million (+60.50%).
- RLMD quarterly CFI is now -59.64% below its all-time high of $40.00 million, reached on March 31, 2023.
Performance
RLMD Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
$47.96 M
+$12.28 M+34.43%
September 30, 2024
Summary
- As of February 26, 2025, RLMD TTM cash flow from investing activities is $47.96 million, with the most recent change of +$12.28 million (+34.43%) on September 30, 2024.
- Over the past year, RLMD TTM CFI has increased by +$27.45 million (+133.84%).
- RLMD TTM CFI is now -31.26% below its all-time high of $69.76 million, reached on March 31, 2023.
Performance
RLMD TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
RLMD Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +155.7% | +60.5% | +133.8% |
| 3 y3 years | +246.5% | -41.3% | +26.2% |
| 5 y5 years | +100.0% | - | - |
RLMD Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +193.2% | -59.6% | +117.7% | -31.3% | +160.2% |
| 5 y | 5-year | at high | +162.9% | -59.6% | +117.7% | -31.3% | +160.2% |
| alltime | all time | at high | +162.9% | -59.6% | +117.7% | -31.3% | +160.2% |
Relmada Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $16.14 M(+15.2%) | $47.96 M(+34.4%) |
| Jun 2024 | - | $14.01 M(+39.3%) | $35.67 M(+74.0%) |
| Mar 2024 | - | $10.06 M(+29.9%) | $20.51 M(-59.4%) |
| Dec 2023 | $50.45 M(+155.7%) | $7.74 M(+100.5%) | $50.45 M(+22.9%) |
| Sep 2023 | - | $3.86 M(-435.2%) | $41.06 M(-40.3%) |
| Jun 2023 | - | -$1.15 M(-102.9%) | $68.75 M(-1.4%) |
| Mar 2023 | - | $40.00 M(-2516.5%) | $69.76 M(+253.5%) |
| Dec 2022 | $19.73 M(-136.5%) | -$1.66 M(-105.2%) | $19.73 M(-128.3%) |
| Sep 2022 | - | $31.56 M(<-9900.0%) | -$69.79 M(-5.5%) |
| Jun 2022 | - | -$140.50 K(-98.6%) | -$73.84 M(-7.2%) |
| Mar 2022 | - | -$10.03 M(-89.0%) | -$79.61 M(+47.1%) |
| Dec 2021 | -$54.12 M(+57.1%) | -$91.18 M(-431.4%) | -$54.12 M(-242.4%) |
| Sep 2021 | - | $27.51 M(-565.3%) | $38.00 M(+152.0%) |
| Jun 2021 | - | -$5.91 M(-138.2%) | $15.08 M(+224.2%) |
| Mar 2021 | - | $15.47 M(+1553.6%) | $4.65 M(-113.5%) |
| Dec 2020 | -$34.45 M(-57.0%) | $935.30 K(-79.6%) | -$34.45 M(-2.6%) |
| Sep 2020 | - | $4.59 M(-128.1%) | -$35.38 M(-11.5%) |
| Jun 2020 | - | -$16.34 M(-30.9%) | -$39.97 M(+69.1%) |
| Mar 2020 | - | -$23.63 M(<-9900.0%) | -$23.63 M(<-9900.0%) |
| Dec 2019 | -$80.16 M(<-9900.0%) | - | - |
| Jun 2019 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 2019 | - | $0.00(0.0%) | -$9800.00(0.0%) |
| Dec 2018 | - | $0.00(-100.0%) | -$9800.00(-21.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | -$12.40 K(-75.1%) | -$9800.00(<-9900.0%) | -$12.40 K(+158.3%) |
| Mar 2018 | - | $0.00(0.0%) | -$4800.00(-80.8%) |
| Dec 2017 | - | $0.00(-100.0%) | -$25.00 K(-8.8%) |
| Sep 2017 | - | -$2600.00(+18.2%) | -$27.40 K(-44.8%) |
| Jun 2017 | -$49.70 K(-91.2%) | -$2200.00(-89.1%) | -$49.60 K(-29.5%) |
| Mar 2017 | - | -$20.20 K(+741.7%) | -$70.40 K(-37.9%) |
| Dec 2016 | - | -$2400.00(-90.3%) | -$113.30 K(-80.7%) |
| Sep 2016 | - | -$24.80 K(+7.8%) | -$585.70 K(+4.2%) |
| Jun 2016 | -$562.30 K(+2313.3%) | -$23.00 K(-63.5%) | -$562.20 K(+3.5%) |
| Mar 2016 | - | -$63.10 K(-86.7%) | -$543.10 K(+12.6%) |
| Dec 2015 | - | -$474.80 K(>+9900.0%) | -$482.30 K(+3345.0%) |
| Sep 2015 | - | -$1300.00(-66.7%) | -$14.00 K(-40.2%) |
| Jun 2015 | -$23.30 K(+529.7%) | -$3900.00(+69.6%) | -$23.40 K(+20.0%) |
| Mar 2015 | - | -$2300.00(-64.6%) | -$19.50 K(+13.4%) |
| Dec 2014 | - | -$6500.00(-39.3%) | -$17.20 K(+60.7%) |
| Sep 2014 | - | -$10.70 K(<-9900.0%) | -$10.70 K(+494.4%) |
| Jun 2014 | -$3700.00(+105.6%) | - | - |
| Feb 2014 | - | $0.00(0.0%) | -$1800.00(0.0%) |
| Nov 2013 | - | $0.00(0.0%) | -$1800.00(0.0%) |
| Aug 2013 | -$1800.00(<-9900.0%) | $0.00(-100.0%) | -$1800.00(0.0%) |
| May 2013 | - | -$1800.00(<-9900.0%) | -$1800.00(<-9900.0%) |
| Feb 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Nov 2012 | - | $0.00 | $0.00 |
| Aug 2012 | $0.00 | - | - |
FAQ
- What is Relmada Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Relmada Therapeutics?
- What is Relmada Therapeutics annual CFI year-on-year change?
- What is Relmada Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Relmada Therapeutics?
- What is Relmada Therapeutics quarterly CFI year-on-year change?
- What is Relmada Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Relmada Therapeutics?
- What is Relmada Therapeutics TTM CFI year-on-year change?
What is Relmada Therapeutics annual cash flow from investing activities?
The current annual CFI of RLMD is $50.45 M
What is the all time high annual CFI for Relmada Therapeutics?
Relmada Therapeutics all-time high annual cash flow from investing activities is $50.45 M
What is Relmada Therapeutics annual CFI year-on-year change?
Over the past year, RLMD annual cash flow from investing activities has changed by +$30.72 M (+155.67%)
What is Relmada Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of RLMD is $16.14 M
What is the all time high quarterly CFI for Relmada Therapeutics?
Relmada Therapeutics all-time high quarterly cash flow from investing activities is $40.00 M
What is Relmada Therapeutics quarterly CFI year-on-year change?
Over the past year, RLMD quarterly cash flow from investing activities has changed by +$6.08 M (+60.50%)
What is Relmada Therapeutics TTM cash flow from investing activities?
The current TTM CFI of RLMD is $47.96 M
What is the all time high TTM CFI for Relmada Therapeutics?
Relmada Therapeutics all-time high TTM cash flow from investing activities is $69.76 M
What is Relmada Therapeutics TTM CFI year-on-year change?
Over the past year, RLMD TTM cash flow from investing activities has changed by +$27.45 M (+133.84%)